Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
174M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
37.1M
-
Shares change
-
+7.68M
-
Total reported value, excl. options
-
$316M
-
Value change
-
+$59.3M
-
Put/Call ratio
-
0.54
-
Number of buys
-
65
-
Number of sells
-
-40
-
Price
-
$8.49
Significant Holders of Wave Life Sciences Ltd. - Common Stock, $0.00001 par value per share (WVE) as of Q3 2020
126 filings reported holding WVE - Wave Life Sciences Ltd. - Common Stock, $0.00001 par value per share as of Q3 2020.
Wave Life Sciences Ltd. - Common Stock, $0.00001 par value per share (WVE) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.1M shares
of 174M outstanding shares and own 21.29% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (7.78M shares), PRIMECAP MANAGEMENT CO/CA/ (3.3M shares), Bellevue Group AG (2.6M shares), PERCEPTIVE ADVISORS LLC (2.5M shares), BlackRock Inc. (2.45M shares), Nantahala Capital Management, LLC (2.38M shares), JPMORGAN CHASE & CO (1.13M shares), MORGAN STANLEY (1.12M shares), Alyeska Investment Group, L.P. (1.07M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1M shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.